The short answer: Coenzyme Q10 (CoQ10) and alpha-lipoic acid (ALA) are biologically interesting antioxidants that participate in mitochondrial energy production and protection against oxidative stress. Because kidney cells have high energy demands, researchers have investigated whether these supplements might support kidney health.
However, mitochondrial evidence is not the same as clinical proof. Most evidence for CoQ10 and ALA in kidney disease comes from laboratory studies, animal experiments, small clinical studies, or research in specific conditions. There is currently not strong evidence that either supplement can prevent CKD progression, reverse kidney damage, or replace established kidney-protective treatment.
Why are mitochondria relevant to the kidneys?
Mitochondria are structures inside cells that produce much of the energy cells need to function.
Kidney cells, particularly those involved in filtering and transporting substances, have substantial energy requirements. In CKD, diabetes, high blood pressure, inflammation, toxins, and some forms of acute kidney injury, researchers have found evidence of oxidative stress and mitochondrial dysfunction.
Oxidative stress occurs when the production of reactive molecules exceeds the body’s ability to control them.
This creates a reasonable scientific question:
If mitochondrial dysfunction contributes to kidney injury, could compounds that support mitochondrial function also protect the kidneys?
The biology is plausible. The clinical answer is much less certain.
What is CoQ10?
Coenzyme Q10 (CoQ10) is a naturally occurring compound found in mitochondria. It helps cells produce energy and also functions as an antioxidant.
Laboratory research suggests that CoQ10 may:
- Support mitochondrial energy production
- Reduce oxidative stress
- Influence inflammatory pathways
- Protect cells from some forms of experimental injury
These effects have generated interest in kidney disease, particularly conditions involving oxidative stress.
But a biochemical effect does not automatically translate into improved eGFR, reduced albuminuria, slower CKD progression, or fewer cases of kidney failure.
Those clinical outcomes require human trials.
What is alpha-lipoic acid?
Alpha-lipoic acid (ALA) is another antioxidant involved in mitochondrial metabolism. It can also help regenerate other antioxidant systems.
ALA has been studied particularly in conditions involving oxidative stress and diabetic complications, including diabetic neuropathy.
Experimental kidney research suggests that ALA can influence oxidative stress and inflammation. Some human studies have also examined metabolic and vascular effects.
However, evidence that ALA independently protects kidney function in people with CKD remains limited.
It should therefore be viewed as a research-supported biological possibility, not an established CKD treatment.
CoQ10 vs ALA: what does the evidence actually show?
The important distinction is between mechanistic evidence and clinical evidence.
Mechanistic evidence: Both compounds have credible biological effects involving mitochondrial function and oxidative stress.
Animal evidence: Experimental models have reported potentially beneficial effects on kidney injury and oxidative stress.
Human evidence: Much less is known about whether supplementation produces meaningful improvements in long-term kidney outcomes.
There is currently no strong evidence that taking CoQ10 or ALA will reliably:
- Increase eGFR
- Stop CKD progression
- Reverse established kidney scarring
- Eliminate albuminuria
- Prevent dialysis
- Replace ACE inhibitors, ARBs, SGLT2 inhibitors, blood-pressure treatment, diabetes management, or other evidence-based therapies
That distinction is essential.
What about diabetic kidney disease?
Diabetes is one setting where mitochondrial dysfunction and oxidative stress have attracted substantial research attention.
Hyperglycemia can increase oxidative stress and alter cellular energy metabolism. Researchers have therefore investigated antioxidants such as CoQ10 and ALA as possible adjunctive therapies.
Some studies have reported improvements in markers such as oxidative stress, blood sugar control, or albuminuria, but these findings are not sufficient to establish either supplement as a standard treatment for diabetic kidney disease.
For someone with diabetic CKD, treatments with established kidney benefits should remain the foundation of care.
Are CoQ10 and ALA safe with CKD?
“Natural” does not automatically mean safe, particularly when kidney function is reduced.
CoQ10
CoQ10 is generally well tolerated in studies, but possible adverse effects include:
- Stomach upset
- Nausea
- Diarrhea
- Headache
It may also interact with some medications. One important example is warfarin, because CoQ10 may affect anticoagulation in some people.
Alpha-lipoic acid
ALA can cause:
- Nausea or gastrointestinal discomfort
- Headache
- Skin reactions in some people
Because ALA can influence glucose metabolism, people taking diabetes medications should discuss its use with their healthcare professional.
The safety evidence is also less reassuring when people with advanced CKD take multiple supplements simultaneously, particularly products with uncertain ingredients or doses.
Does CKD change supplement safety?
Yes.
As kidney function declines, the handling of some substances and their metabolites can change. CKD also commonly involves multiple medications, making interactions more important.
This is one reason a supplement that appears harmless in a healthy adult should not automatically be assumed to have the same risk profile in someone with advanced CKD.
People on dialysis, those with advanced CKD, pregnant individuals, and people taking multiple medications should be particularly cautious about starting supplements without professional review.
What should you monitor?
If someone with CKD is considering CoQ10 or ALA, the goal should not be to judge effectiveness based on how they feel alone.
Kidney disease is better followed using objective information such as:
- eGFR, an estimate of kidney filtration
- Creatinine
- Urine albumin-to-creatinine ratio (UACR) when appropriate
- Blood pressure
- Potassium and other relevant electrolytes
- Blood glucose or HbA1c in diabetes
A single eGFR change does not automatically prove that a supplement helped or harmed the kidneys. Hydration, illness, medications, muscle mass, and normal biological variation can affect kidney-related measurements.
Long-term trends are much more informative.
Should CoQ10 or ALA be used as kidney treatments?
At present, the evidence does not justify treating either supplement as a proven kidney-protective therapy.
If someone with CKD is interested in these supplements, a sensible approach is to discuss:
- The specific kidney condition and its cause.
- Current eGFR and urine albumin/protein results.
- Other medications and supplements being taken.
- Blood pressure and diabetes control when relevant.
- The proposed supplement, dose, product quality, and reason for taking it.
- How kidney function will continue to be monitored.
Most importantly, a supplement should not replace therapies with demonstrated benefits for the person’s particular form of CKD.
Bottom line
CoQ10 and alpha-lipoic acid have plausible mitochondrial and antioxidant effects, and experimental research provides reasons to study them in kidney disease. But the clinical evidence is not strong enough to call either supplement a proven treatment for CKD.
The key distinction is:
Mitochondrial mechanism → promising biological hypothesis → early/limited clinical evidence → not yet established kidney protection.
For someone with CKD, controlling the factors known to drive kidney damage—such as high blood pressure, diabetes, albuminuria, cardiovascular risk, and medication-related kidney risks—remains much more important than relying on an antioxidant supplement.